Fig. 2.
Fig. 2. Differences in cellular resistance between DS AML and non-DS AML for (A) cytarabine (Ara-C) and daunorubicin (DNR), (B) etoposide and 6-thioguanine (6-TG), (C) vincristine (VCR) and prednisolone (Pred), (D) L-asparaginase (L-ASP) and ifosfamide (Ifos). / DS AML is significantly more sensitive to cytarabine (median, 11.5-fold), daunorubicin (2.2-fold), etoposide (20.1-fold), 6-thioguanine (2.7-fold), vincristine (23.0-fold), and prednisolone (more than 1.1-fold). However, the differences for L-asparaginase and 4-hydroperoxy ifosfamide were not significant. The median LC50 value is depicted as a horizontal solid line, and the 25th and 75th percentiles are depicted as triangles. More results are shown in Table 2.

Differences in cellular resistance between DS AML and non-DS AML for (A) cytarabine (Ara-C) and daunorubicin (DNR), (B) etoposide and 6-thioguanine (6-TG), (C) vincristine (VCR) and prednisolone (Pred), (D) L-asparaginase (L-ASP) and ifosfamide (Ifos).

DS AML is significantly more sensitive to cytarabine (median, 11.5-fold), daunorubicin (2.2-fold), etoposide (20.1-fold), 6-thioguanine (2.7-fold), vincristine (23.0-fold), and prednisolone (more than 1.1-fold). However, the differences for L-asparaginase and 4-hydroperoxy ifosfamide were not significant. The median LC50 value is depicted as a horizontal solid line, and the 25th and 75th percentiles are depicted as triangles. More results are shown in Table 2.

Close Modal

or Create an Account

Close Modal
Close Modal